Ocular Therapeutix, Inc. (OCUL)
NasdaqGM · USD · Healthcare · Biotechnology
$6.47 (-0.46%) as of
Key statistics
- Market cap
- 1.42B
- Forward P/E
- -4.37
- EPS (TTM)
- -1.40
- Dividend yield
- 0.00%
- 52-week range
- 6.00 – 16.44
- Beta
- 0.99
- Revenue (TTM)
- 52.05M
- Profit margin
- 0.00%
- Analyst target
- $25.45
- Volume
- 1.69M
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Bedford, MA, United States
- Employees
- 325
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.